Company: MLTX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001821586-25-000022
Chunk: 108

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 108
---
, where all the outstanding awards (whether currently outstanding or granted in the future) would have been deemed fully vested. ESOPNumber of OptionsWeighted-Average Exercise PriceAggregate Intrinsic Value (in thousands)Weighted-Average Remaining Contractual Term (in years)Awards outstanding as of January 1, 202598,3931.505,1806.73Awards exercised for the nine months ended September 30, 2025(93,347)1.30n/an/aAwards forfeited for the nine months ended September 30, 2025(5,046)5.25n/an/aAwards outstanding as of September 30, 2025————Awards exercisable as of September 30, 2025————MoonLake Immunotherapeutics 2022 Equity Incentive PlanOn April 5, 2022 (the “Effective Date”), the Company created the Equity Incentive Plan to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation. The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the 10th anniversary of the Effective Date.

27

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025(Unaudited)

Equity Incentive Plan (Options)Number of OptionsWeighted-Average Exercise PriceAggregate Intrinsic Value (in thousands)Weighted-Average Remaining Contractual Term (in years)Awards outstanding as of January 1, 2025972,476$24.94$28,5888.18Awards granted for the nine months ended September 30, 2025563,332$43.19n/an/aAwards exercised for the nine months ended September 30, 2025(27,149)$17.68n/an/aAwards forfeited for the nine months ended September 30, 2025(67,919)$47